var data={"title":"Metformin: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Metformin: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6545?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=metformin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Metformin: Patient drug information&quot;</a> and <a href=\"topic.htm?path=metformin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Metformin: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709034\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Lactic acidosis</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Metformin-associated lactic acidosis was characterized by elevated blood lactate levels (&gt;5 mmol/L), anion gap acidosis (without evidence of ketonuria or ketonemia), and increased lactate/pyruvate ratio; and metformin plasma levels generally &gt;5 mcg/mL.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (eg, carbonic anhydrase inhibitors such as topiramate), &ge;65 years, having a radiological study with contrast, surgery and other procedures, hypoxic states (eg, acute congestive heart failure), excessive alcohol intake, and hepatic impairment.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Steps to reduce the risk of and manage metformin-associated lactic acidosis in these high risk groups are provided in the full prescribing information.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">If metformin-associated lactic acidosis is suspected, immediately discontinue metformin and institute general supportive measures in a hospital setting. Prompt hemodialysis is recommended.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193858\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>D-Care DM2;</li>\n      <li>Fortamet;</li>\n      <li>Glucophage;</li>\n      <li>Glucophage XR;</li>\n      <li>Glumetza;</li>\n      <li>Riomet</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193859\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Glucophage;</li>\n      <li>Glumetza;</li>\n      <li>Glycon</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193907\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antidiabetic Agent, Biguanide</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193863\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diabetes mellitus, type 2:</b> Oral: <b>Note:</b> Clinically significant responses may not be seen at doses &lt;1,500 mg/day; however, a lower recommended starting dose and gradual increased dosage is recommended to minimize GI symptoms. If HbA<sub>1c</sub> is &ge;9% at initiation of therapy consider dual therapy (metformin + a second antihyperglycemic agent) (ADA 2018a).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Immediate-release tablet or solution:</i> Adults &ge;17 years:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Initial: Manufacturer labeling: 500 mg twice daily <b>or</b> 850 mg once daily; alternatively, an initial dose of 500 mg once daily has been recommended (Nathan 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Titrate in increments of 500 mg weekly <b>or</b> 850 mg every other week; may also titrate from 500 mg twice a day to 850 mg twice a day after 2 weeks; usual effective dose is 850 to 1,000 mg twice daily; modest additional benefit may be observed with doses up to ~2,500 mg/day but their use may be limited by adverse GI effects (Nathan 2009). If a dose &gt;2,000 mg/day is considered, it may be better tolerated in 3 divided doses; maximum recommended dose: 2,550 mg/day.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Extended-release tablet:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Initial: 500 to 1,000 mg once daily; dosage may be increased by 500 mg weekly up to a maximum of 2,000 mg/day (Glucophage XR, Glumetza) or 2,500 mg/day (Fortamet). If glycemic control is not achieved at maximum dose, may divide dose and administer twice daily.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Conversion from immediate-release to extended-release tablets:</i> Patients receiving metformin immediate release may be switched to metformin ER once daily at the same total daily dose, up to 2,000 mg once daily (2,500 mg for Fortamet)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Transfer from other antidiabetic agents:</i> No transition period is generally necessary except when transferring from chlorpropamide. When transferring from chlorpropamide, care should be exercised during the first 2 weeks because of the prolonged retention of chlorpropamide in the body, leading to overlapping drug effects and possible hypoglycemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Concomitant use with insulin or insulin secretagogues:</i> Reduced dose of insulin or insulin secretagogues (eg, sulfonylureas) may be needed.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Antipsychotic-induced weight gain (off-label use):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Immediate-release</i>: Oral: Initial: 250 to 500 mg twice daily; may increase after 3 to 7 days to 500 mg two or three times daily based on tolerability. Doses as high as 2,550 mg/day have been studied (Chen 2013, de Silva 2016, Wang 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Extended-release</i>: Oral: Initial: 500 mg once daily for 2 to 6 weeks, then increase to 1,000 mg once daily; may continue dosage increases in 500 mg increments every 6 weeks based on tolerability up to 2,000 mg/day (Carrizo 2009, Rado 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b> Diabetes mellitus, type 2, prevention (off-label use): </b> <i>Immediate-release tablet or solution:</i> Oral: Initial: 850 mg once daily; Target: 850 mg twice daily (Knowler 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Polycystic ovary syndrome with anovulatory infertility (off-label use):</b> Females: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Immediate release:</i> 1,500 to 2,000 mg/day in 2 or 3 divided doses (Johnson 2010; Moll 2006; Morin-Papunen 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Extended release:</i> 1,000 mg twice daily (Legro 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Metformin should be initiated at lower doses (500 mg daily) and increased gradually over 1 to 2 weeks to the target dose to minimize adverse effects (eg, GI intolerance) (Johnson 2010; Legro 2007; Moll 2006; Morin-Papunen 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Polycystic ovary syndrome with menstrual irregularities (off-label use): </b> Females: Oral: <i>Immediate release:</i> 500 mg 2 or 3 times daily, up to 1,000 mg twice daily (Costello 2007; Morin-Papunen 2003; Meyer 2007; Moghetti 2000). The dose of metformin should be increased gradually to minimize GI adverse effects (Meyer 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> When metformin is used, cyclic progestin therapy may be added for the first 6 months of metformin treatment, until regular cycles are established.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prevention of ovarian hyperstimulation syndrome with polycystic ovary syndrome (off-label use): </b> Females: Oral: <i>Immediate release: </i>1,000 mg to 2,550 mg per day as 500 mg 2 or 3 times per day <b>or</b> 850 mg 2 or 3 times per day (Palomba 2013; Palomba 2011; Tang 2006; Tso 2014). The dose of metformin should be increased gradually to minimize GI adverse effects.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Pretreatment with metformin may be started as early as 16 weeks prior (but typically 4 to 5 weeks prior) to as late as the first day of gonadotropin-releasing hormone (GnRH) agonist administration; some studies continued metformin therapy during gonadotropin ovarian stimulation (Tso 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193885\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=metformin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Metformin: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Diabetes mellitus, type 2:</b> Oral: <b>Note:</b> Clinically significant responses may not be seen at doses &lt;1,500 mg daily; however, a lower recommended starting dose and gradual increased dosage is recommended to minimize gastrointestinal symptoms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Immediate-release tablet or solution: </i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Manufacturer&rsquo;s labeling:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;10 years and Adolescents &le;16 years: Initial: 500 mg twice daily; increases in daily dosage should be made in increments of 500 mg at weekly intervals, given in divided doses, up to a maximum of 2,000 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents &ge;17 years: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Off-label dosing: Children &ge;10 years and Adolescents &lt;18 years: Initial: 500 mg once daily for 7 days, then increase in 500 mg increments at 1- to 2-week intervals to a target dose of 1,000 mg twice daily; maximum: 2,000 mg/day (AAP [Copeland 2013]; ISPAD [Zeitzler 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Extended-release tablet:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;10 years and Adolescents &le;16 years (off-label): Limited data available: Initial: 500 mg once daily; dosage may be increased by 500 mg at 1- to 2-week intervals; maximum dose: 2,000 mg/day (AAP [Copeland 2013]; ISPAD [Zeitzler 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adolescents &ge;17 years: Fortamet, Glucophage XR: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193864\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing. The initial and maintenance dosing should be conservative, due to the potential for decreased renal function (monitor).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193865\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">eGFR &gt;45 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary; monitor renal function at least annually. More frequent monitoring (every 3 to 6 months) and a maximum dose of 2,000 mg/day has been recommended for patients with eGFR &gt;45 to &lt;60 mL/minute/1.73 m<sup>2</sup> (ADA [Lipska 2011]; Inzucchi 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">eGFR 30 to 45 mL/minute/1.73 m<sup>2</sup>:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Preexisting impairment: </i>Use is not recommended for initiation of therapy by some experts (AACE [Garber 2017]; ADA [Lipska 2011]; Inzucchi 2014); however, others recommend that in the absence of active kidney disease and/or conditions that predispose to hypoperfusion and hypoxemia (eg, acute heart failure, dehydration) therapy may be initiated at half the usual initial dose (eg, 250 mg/day) with close monitoring and titration (maximum: 1,000 mg/day) (McCulloch 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>If eGFR falls between</i>\n      <i> 30 to &lt;45 mL/minute/1.73 m</i>\n      <i>\n        <sup>2</sup></i>\n      <i> during therapy</i>: Consider benefits/risks of continuing therapy. If continuing therapy, a dosage reduction of 50% (maximum: 1,000 mg/day) and monitoring of renal function every 3 months is recommended (ADA [Lipska 2011]; Inzucchi 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>: Use is contraindicated.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193866\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">The manufacturer recommends avoiding metformin since liver disease is considered a risk factor for the development of lactic acidosis during metformin therapy. However, continued use of metformin in diabetics with liver dysfunction, including cirrhosis, has been used successfully and may be associated with a survival benefit in carefully selected patients; use cautiously in patients at risk for lactic acidosis (eg, renal impairment, alcohol use) (Brackett 2010; Zhang 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193832\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, Combination: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">D-Care DM2: Extended release tablet, as hydrochloride: 500 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Riomet: 500 mg/5 mL (118 mL, 473 mL) [contains propylene glycol; strawberry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Riomet: 500 mg/5 mL (118 mL, 473 mL) [contains saccharin calcium; cherry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Glucophage: 500 mg, 850 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Glucophage: 1000 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg, 850 mg, 1000 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release 24 Hour, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Fortamet: 500 mg, 1000 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Glucophage XR: 500 mg, 750 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Glumetza: 500 mg, 1000 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg, 750 mg, 1000 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193817\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25484130\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Extended release tablets utilize differing release mechanisms: Glucophage XR uses dual hydrophilic polymer matrix systems, Fortamet uses single-composition osmotic technology, and Glumetza uses gastric retention technology.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20344698\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet, oral, as hydrochloride:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Glycon: 500 mg, 850 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193837\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Administer with a meal (to decrease GI upset).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Extended release: Swallow whole; do not crush, break, or chew. Administer once daily doses with the evening meal. Fortamet should also be administered with a full glass of water.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193836\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diabetes mellitus, type 2:</b> Management of type 2 diabetes mellitus (noninsulin dependent, NIDDM) when hyperglycemia cannot be managed with diet and exercise alone.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> If not contraindicated and if tolerated, metformin is the preferred initial pharmacologic agent for type 2 diabetes management (ADA 2018a).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25730693\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Antipsychotic-induced weight gain; Diabetes mellitus, type 2 (prevention); Gestational diabetes mellitus (GDM); Polycystic ovary syndrome in women with anovulatory infertility; Polycystic ovary syndrome in women with menstrual irregularities; Prevention of ovarian hyperstimulation syndrome in women with polycystic ovary syndrome</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193915\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">MetFORMIN may be confused with metroNIDAZOLE</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Glucophage may be confused with Glucotrol, Glutofac</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs that have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Dianben [Spain] may be confused with Diovan brand name for valsartan [U.S., Canada, and multiple international markets]. </p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Glucon brand name for metformin [Malaysia, Singapore] is also the brand name for glucosamine [Singapore]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193824\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea (IR tablet: 12% to 53%; ER tablet: 10% to 17%), nausea and vomiting (IR tablet: 26%; ER tablet: 7%), flatulence (4% to 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Infection (21%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Chest discomfort, flushing, palpitations</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (5% to 6%), chills, dizziness, taste disorder</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Diaphoresis, nail disease, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Decreased vitamin B<sub>12</sub> serum concentrate (7%), hypoglycemia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (7% to 9%), dyspepsia (&le;7%), abdominal distress (6%), abdominal pain (3% to 4%), abdominal distention, abnormal stools, constipation, heartburn</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Weakness (9%), myalgia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Rhinitis (4% to 6%), dyspnea, flu-like symptoms, upper respiratory tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Accidental injury (6% to 7%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing and/or case reports: Hepatic injury (cholestatic, hepatocellular, and mixed), lactic acidosis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193840\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>US labeling:</i> Hypersensitivity to metformin or any component of the formulation; severe renal dysfunction (eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>); acute or chronic metabolic acidosis with or without coma (including diabetic ketoacidosis).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <i>Canadian labeling:</i> Hypersensitivity to metformin or any component of the formulation; renal function unknown, renal impairment, and serum creatinine levels above the upper limit of normal range; renal disease or renal dysfunction (serum creatinine &ge;136 micromol/L in males or &ge;124 micromol/L in females or abnormal creatinine clearance &lt;60 mL/minute) which may result from conditions such as cardiovascular collapse (shock), acute myocardial infarction, and septicemia; unstable and/or insulin-dependent (type I) diabetes mellitus; acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma, history of ketoacidosis with or without coma; history of lactic acidosis (regardless of precipitating factors); excessive alcohol intake (acute or chronic); severe hepatic dysfunction or clinical or laboratory evidence of hepatic disease; cardiovascular collapse and disease states associated with hypoxemia including cardiorespiratory insufficiency, which are often associated with hyperlactacidemia; stress conditions (eg, severe infection, trauma, surgery and postoperative recovery phase); severe dehydration; pregnancy; breast-feeding</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193821\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lactic acidosis: <b>[US Boxed Warning]: </b><b>Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset is often subtle, accompanied by nonspecific symptoms (eg, malaise, myalgias, respiratory distress, somnolence, abdominal pain); elevated blood lactate levels (&gt;5 mmol/L); anion gap acidosis (without evidence of ketonuria or ketonemia); increased lactate:pyruvate ratio; metformin plasma levels generally &gt;5 mcg/mL. Risk factors for lactic acidosis include patients with renal impairment, concomitant use of certain drugs (eg, carbonic anhydrase inhibitors such as topiramate), &ge;65 years, having a radiologic study with contrast, surgery and other procedures, hypoxic states (eg, acute heart failure), excessive alcohol intake, and hepatic impairment. Discontinue immediately if lactic acidosis is suspected; prompt hemodialysis is recommended.</b> Lactic acidosis should be suspected in any patient with diabetes receiving metformin with evidence of acidosis but without evidence of ketoacidosis. Discontinue use in patients with conditions associated with dehydration, hypoperfusion, sepsis, or hypoxemia. Temporarily discontinue therapy in patients with restricted food and fluid intake. The risk of accumulation and lactic acidosis increases with the degree of impairment of renal function.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vitamin B<sub>12</sub> concentrations: Long-term metformin use is associated with vitamin B<sub>12</sub> deficiency; monitor vitamin B<sub>12</sub> serum concentrations periodically with long-term therapy. Monitoring of B<sub>12</sub> serum concentrations should be considered in all patients receiving metformin and in particular those with peripheral neuropathy or anemia (ADA 2018d).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Heart failure: Metformin may be used in patients with stable heart failure (HF); avoid use in unstable or hospitalized patients with heart failure (ADA 2018h). Risk of lactic acidosis may be increased secondary to hypoperfusion. In a scientific statement from the American Heart Association, metformin has been determined to be an agent that may exacerbate underlying myocardial dysfunction (magnitude: major) (AHA [Page 2016]). Use of metformin in patients with HF may be associated with reduced mortality and reduction in hospital readmission for HF (Crowley 2017; Eurich 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: The manufacturer recommends to generally avoid use in patients with hepatic impairment due to potential for lactic acidosis. However, continued use of metformin in patients with diabetes with liver dysfunction, including cirrhosis, may be associated with a survival benefit in carefully selected patients (Brackett 2010; Crowley 2017; Zhang 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Metformin is substantially excreted by the kidney; assess renal function prior to initiation of therapy and periodically thereafter using estimated glomerular filtration rate (eGFR); the risk of metformin accumulation and lactic acidosis increases with degree of renal impairment. Use is contraindicated in patients with eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>. Assess benefits/risks of metformin use in patients with eGFR 30 to 45 mL/minute/1.73 m<sup>2</sup>; if used, dosage reduction is recommended (ADA [Lipska 2011]; Inzucchi 2014; McCulloch 2017). Some experts recommend avoiding initiation of metformin in these patients (AACE [Garber 2017]; ADA [Lipska 2011]; Inzucchi 2014), while others suggest initiation may be reasonable in the absence of active kidney disease and/or conditions that predispose to hypoperfusion and hypoxemia (McCulloch 2017). Use of concomitant medications that may affect renal function (ie, affect tubular secretion) may also affect metformin disposition. Metformin should be withheld in patients with dehydration and/or prerenal azotemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Stress-related states: It may be necessary to discontinue metformin and administer insulin if the patient is exposed to stress (fever, trauma, infection, surgery).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution; risk of metformin associated lactic acidosis increases with age.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extended-release tablet: Insoluble tablet shell (Glumetza 1,000 mg tablet) may remain intact and be visible in the stool. Other extended-released tablets (Fortamet, Glucophage XR, Glumetza 500 mg) may appear in the stool as a soft mass resembling the tablet.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>&bull; </i>Appropriate use<i>: </i>Not indicated for use in patients with type 1 diabetes mellitus or with diabetic ketoacidosis (DKA).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ethanol use: Instruct patients to avoid excessive acute or chronic ethanol use; ethanol may potentiate metformin's effect on lactate metabolism.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Iodinated contrast: Temporarily discontinue metformin at the time of or before iodinated contrast imaging procedures in patients with an eGFR 30 to 60 mL/minute/1.73 m<sup>2</sup>; or with a history of hepatic disease, alcoholism, or heart failure; or in patients who will receive intra-arterial iodinated contrast. Reevaluate eGFR 48 hours after imaging procedure; restart if renal function is stable. Alternatively, the American College of Radiology (ACR) guidelines recommend that metformin may be used prior to or following administration of iodinated contrast media in patients with no evidence of acute kidney injury (AKI) and with an eGFR &ge;30 mL/minute/1.73 m<sup>2</sup>; ACR guidelines recommend temporary discontinuation of metformin in patients with known AKI or severe chronic kidney disease ([stage IV or V [ie, eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>]) or who are undergoing arterial catheter studies (ACR 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Patient education: Diabetes self-management education (DSME) is essential to maximize the effectiveness of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Surgical procedures: Metformin should be withheld the day of surgery (all other oral hypoglycemic agents should be withheld the morning of surgery or procedure) (ADA 2018e). Restart only after normal oral intake resumed and normal renal function is verified.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299680\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of OCT2</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193826\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9621&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Abemaciclib: May increase the serum concentration of MetFORMIN.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): May enhance the adverse/toxic effect of MetFORMIN. Specifically, alcohol may potentiate the risk of lactic acidosis<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha-Lipoic Acid: May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Androgens: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<b> Exceptions: </b>Danazol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bictegravir: May increase the serum concentration of MetFORMIN.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BuPROPion: May increase the serum concentration of OCT2 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Carbonic Anhydrase Inhibitors: May enhance the adverse/toxic effect of MetFORMIN. Specifically, the risk of developing lactic acidosis may be increased.<b> Exceptions: </b>Brinzolamide; Dorzolamide.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephalexin: May increase the serum concentration of MetFORMIN.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cimetidine: May increase the serum concentration of MetFORMIN. Management: Consider alternatives to cimetidine in patients receiving metformin due to a potential for increased metformin concentrations and toxicity (including lactic acidosis).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dalfampridine: MetFORMIN may increase the serum concentration of Dalfampridine. Dalfampridine may increase the serum concentration of MetFORMIN. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dofetilide: MetFORMIN may increase the serum concentration of Dofetilide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dolutegravir: May increase the serum concentration of MetFORMIN. Management: Limit the daily metformin dose to 1,000 mg when used together with dolutegravir.  Metformin dose adjustments may also be needed upon discontinuation of dolutegravir.  Monitor patient response to metformin closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glycopyrrolate (Systemic): May increase the serum concentration of MetFORMIN.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Guanethidine: May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyperglycemia-Associated Agents: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypoglycemia-Associated Agents: Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemia-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iodinated Contrast Agents: May enhance the adverse/toxic effect of MetFORMIN. Renal dysfunction that may be caused by iodinated contrast agents may lead to metformin-associated lactic acidosis. Management: Management advice varies. Refer to the full drug interaction monograph content for details.<b> Exceptions: </b>Diatrizoate Meglumine; Diatrizoate Sodium; Ethiodized Oil.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Isavuconazonium Sulfate: May increase the serum concentration of MetFORMIN.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">LamoTRIgine: May increase the serum concentration of MetFORMIN. Management: The lamotrigine Canadian product monograph states that coadministration of these drugs is not recommended.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ombitasvir, Paritaprevir, and Ritonavir: May enhance the adverse/toxic effect of MetFORMIN. Specifically, the risk for lactic acidosis may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir: May enhance the adverse/toxic effect of MetFORMIN. Specifically, the risk for lactic acidosis may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ondansetron: May increase the serum concentration of MetFORMIN.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Patiromer: May decrease the serum concentration of MetFORMIN. Management: Administer metformin at least 3 hours before or 3 hours after patiromer.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pegvisomant: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prothionamide: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinolones: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Quinolones may diminish the therapeutic effect of Blood Glucose Lowering Agents. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ranolazine: May increase the serum concentration of MetFORMIN. Management: Limit the metformin dose to a maximum of 1700 mg/day when used together with ranolazine 1000 mg twice daily.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritodrine: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topiramate: May enhance the adverse/toxic effect of MetFORMIN.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimethoprim: May increase the serum concentration of MetFORMIN.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trospium: MetFORMIN may decrease the serum concentration of Trospium. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vandetanib: May increase the serum concentration of MetFORMIN.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Verapamil: May diminish the therapeutic effect of MetFORMIN.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193854\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Food decreases the extent and slightly delays the absorption. Management: Administer with a meal.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193828\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193843\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Metformin has been found to cross the placenta in concentrations which may be comparable to those found in the maternal plasma. Pharmacokinetic studies suggest that clearance of metformin may increase during pregnancy and dosing may need adjusted in some women when used during the third trimester (Charles 2006; de Oliveira Baraldi 2011; Eyal 2010; Gardiner 2003; Hughes 2006; Vanky 2005).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">An increased risk of birth defects or adverse fetal/neonatal outcomes has not been observed following maternal use of metformin for GDM or type 2 diabetes when glycemic control is maintained (Balani 2009; Coetzee 1979; Coetzee 1984; Ekpebegh 2007; Niromanesh 2012; Rowan 2008; Rowan 2010; Tertti 2008). However, available guidelines note that long-term safety data is not available (ACOG 190 2018; ADA 2018c)</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In women with diabetes, maternal hyperglycemia can be associated with congenital malformations as well as adverse effects in the fetus, neonate, and the mother (ACOG 2005; ADA 2018c; Metzger 2007). To prevent adverse outcomes, prior to conception and throughout pregnancy maternal blood glucose and HbA<sub>1c</sub> should be kept as close to target goals as possible but without causing significant hypoglycemia (ADA 2018c; Blumer 2013). Agents other than metformin are currently recommended to treat diabetes in pregnant women (ADA 2018c). However metformin may be used as an alternative agent in some patients requiring therapy for gestational diabetes mellitus (ACOG 190 2018).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193844\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Metformin is present in breast milk.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The relative infant dose (RID) of metformin is 1.08% when calculated using the highest average breast milk concentration located and compared to a weight-adjusted maternal dose of 6.55 mg/kg/day.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In general, breastfeeding is considered acceptable when the RID is &lt;10 (Anderson 2016; Ito 2000).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The RID of metformin was calculated using a milk concentration of 0.47 mcg/mL, providing an estimated daily infant dose via breast milk of 0.07 mg/kg/day. This milk concentration was obtained following maternal administration of metformin 500 mg twice daily and the RID was calculated using the actual weight of the woman in the study (Briggs 2005).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Small amounts of metformin have been detected in the serum of breastfeeding infants. Because breast milk concentrations of metformin stay relatively constant, avoiding breastfeeding around peak plasma concentrations in the mother would not be helpful in reducing metformin exposure to the infant (Briggs 2005; Eyal 2010; Gardiner 2003; Hale 2002).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">According to the manufacturer, due to the potential for hypoglycemia in the breastfeeding infant, a decision should be made whether to discontinue breastfeeding or to discontinue the drug, taking into account the importance of treatment to the mother. However, breastfeeding is encouraged for all women, including those with diabetes (ACOG 2005; ADA 2018c; Blumer 2013; Metzger 2007). Metformin may be used in breastfeeding women (Blumer 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193845\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Drug may cause GI upset; take with food (to decrease GI upset). Take at the same time(s) each day. Dietary modification based on ADA recommendations is a part of therapy. Monitor for signs and symptoms of vitamin B<sub>12</sub> and/or folic acid deficiency; supplementation may be required.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193830\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Urine for glucose and ketones, fasting blood glucose, hemoglobin A<sub>1c</sub> (at least twice yearly in patients who have stable glycemic control and are meeting treatment goals; quarterly in patients not meeting treatment goals or with therapy change [ADA 2018g]). Initial and periodic monitoring of hematologic parameters (eg, hemoglobin/hematocrit and red blood cell indices); renal function (eGFR) prior to therapy initiation and at least annually (more often in patients at risk of developing renal impairment; every 3 to 6 months if eGFR 45 to &lt;60 mL/minute/1.73 m<sup>2</sup>; every 3 months if eGFR 30 to &lt;45 mL/minute/1.73 m<sup>2</sup> [Lipska 2011]). Monitor vitamin B<sub>12</sub> serum concentrations periodically with long-term therapy; folate (if megaloblastic anemia is suspected).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193833\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Recommendations for glycemic control in nonpregnant adults with diabetes (ADA 2018g):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">HbA<sub>1c</sub>: &lt;7% (a more aggressive [&lt;6.5%] or less aggressive [&lt;8%] HbA<sub>1c</sub> goal may be targeted based on patient-specific characteristics)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Preprandial capillary blood glucose: 80 to 130 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Peak postprandial capillary blood glucose: &lt;180 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Recommendations for glycemic control in older adults (&ge;65 years) with diabetes (ADA 2018b):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">HbA<sub>1c</sub>: &lt;7.5% (healthy); &lt;8% (complex/intermediate health); &lt;8.5% (very complex/poor health) (individualization may be appropriate based on patient and caregiver preferences)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Preprandial capillary blood glucose: 90 to 130 mg/dL (healthy); 90 to 150 mg/dL (complex/intermediate health); 100 to 180 mg/dL (very complex/poor health)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bedtime capillary blood glucose: 90 to 150 mg/dL (healthy); 100 to180 mg/dL (complex/intermediate health); 110 to 200 mg/dL (very complex/poor health)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Recommendations for glycemic control in pediatric (all age groups) patients (ADA 2018f): HbA<sub>1c</sub>: &lt;7.5% (individualization may be appropriate based on patient-specific characteristics; &lt;7% is reasonable if it can be achieved without excessive hypoglycemia)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193820\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Decreases hepatic glucose production, decreasing intestinal absorption of glucose and improves insulin sensitivity (increases peripheral glucose uptake and utilization)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193839\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Within days; maximum effects up to 2 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: 654 &plusmn; 358 L; partitions into erythrocytes; concentrates in liver, kidney, and GI tract</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: Negligible</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Not metabolized by the liver</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Absolute: Fasting: 50% to 60% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Plasma: 4 to 9 hours; Blood ~17.6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: Immediate release: 2 to 3 hours; Extended release: 7 hours (range: 4 to 8 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (90% as unchanged drug; active secretion) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193842\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (D-Care DM2 Combination)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (110): $1,489.02</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Riomet Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg/5 mL (118 mL): $199.07</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (Fortamet Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (60): $2,530.12</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 mg (60): $2,530.12</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (Glucophage XR Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $120.92</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">750 mg (100): $181.42</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (Glumetza Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $6,177.60</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 mg (90): $12,023.64</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (MetFORMIN HCl ER (MOD) Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $5,559.22</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 mg (90): $10,820.08</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (MetFORMIN HCl ER (OSM) Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (60): $1,034.64</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 mg (60): $1,884.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (MetFORMIN HCl ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $74.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">750 mg (100): $119.70</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Glucophage Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $118.48</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">850 mg (100): $201.41</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 mg (100): $244.04</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (MetFORMIN HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $70.43</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">850 mg (100): $119.70</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 mg (500): $721.24</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193846\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Adecco (ID);</li>\n      <li>Ansures (MY, PH);</li>\n      <li>Bentic (PY);</li>\n      <li>Biguax (CO);</li>\n      <li>Dabex (MX);</li>\n      <li>Dainipron (HK);</li>\n      <li>Deson (TH);</li>\n      <li>DH-Metglu 850 (VN);</li>\n      <li>DH-Metglu XR 1000 (VN);</li>\n      <li>Diabemet (MY);</li>\n      <li>Diabetase (DE);</li>\n      <li>Diabetmin (HK, MY, SG);</li>\n      <li>Diabetmin Retard (HK);</li>\n      <li>Diabetmin XR (SG);</li>\n      <li>Diabetol (PY);</li>\n      <li>Diabex (AU, KR);</li>\n      <li>Diabex XR (AU);</li>\n      <li>Diafat (PH);</li>\n      <li>Diaformin (BR, HK, TW, UA);</li>\n      <li>Diaformin XR (AU, ID);</li>\n      <li>Diaformina (UY);</li>\n      <li>Diaformina LP (UY);</li>\n      <li>Dialon (AE, BH, KW, LB, QA, SA);</li>\n      <li>Diamet (JO);</li>\n      <li>Dianben (ES);</li>\n      <li>Diaslim (TH);</li>\n      <li>Diformin (FI);</li>\n      <li>Diformin Retard (FI);</li>\n      <li>Dimefor (CO, MX, PE);</li>\n      <li>Dimet (ET);</li>\n      <li>Emnorm (NZ);</li>\n      <li>Euform Retard (PH);</li>\n      <li>Fordica 500 XR (ID);</li>\n      <li>Formet (AU, JO, MY);</li>\n      <li>Formin (BD, IN);</li>\n      <li>Formit (AE, BH, KW, QA, SA);</li>\n      <li>Fornidd (PH);</li>\n      <li>Glafornil (CL);</li>\n      <li>Glibudon (TW);</li>\n      <li>Glicenex (EC);</li>\n      <li>Glicophage (RO);</li>\n      <li>Glifage (BR);</li>\n      <li>Gliformin (CO);</li>\n      <li>Glisulin XR (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Gluciophage XR (VN);</li>\n      <li>Gluco (TH);</li>\n      <li>Glucodown (KR);</li>\n      <li>Glucofage (EC, VE);</li>\n      <li>Glucofor (ID);</li>\n      <li>Glucoform (PH);</li>\n      <li>Glucogen (KR);</li>\n      <li>Glucoles (TH);</li>\n      <li>Glucomet (AU, ET, SG);</li>\n      <li>Glucomin (IL);</li>\n      <li>Glucomine (TW);</li>\n      <li>Glucon (MY);</li>\n      <li>Glucophage (AE, AR, AT, AU, BB, BE, BF, BH, BJ, BM, BS, BZ, CH, CI, CN, CY, CZ, DK, EE, EG, ET, FI, FR, GB, GH, GM, GN, GR, GY, HK, HR, ID, IE, IL, IN, IQ, IR, IS, IT, JM, JO, KE, KW, LB, LR, LU, LV, LY, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NO, OM, PE, PH, PK, PT, QA, RU, SA, SC, SD, SE, SI, SK, SL, SN, SR, SY, TN, TR, TT, TW, TZ, UG, VN, YE, ZA, ZM, ZW);</li>\n      <li>Glucophage Forte (CZ, NL, PH);</li>\n      <li>Glucophage Retard (EG, IL, QA);</li>\n      <li>Glucophage SR (GB, IE);</li>\n      <li>Glucophage XR (AE, BB, CN, HK, KW, LB, MY);</li>\n      <li>Glucophage-Mite (DE);</li>\n      <li>Glucotika (ID);</li>\n      <li>Glucotin (PH);</li>\n      <li>Gludepatic (ID);</li>\n      <li>Glufor (ID, IL);</li>\n      <li>Glumet (MY, PH);</li>\n      <li>Glumet DC (MY);</li>\n      <li>Glumet Forte (HK);</li>\n      <li>Glumet XR (PH);</li>\n      <li>Glumin (ID);</li>\n      <li>Glumin XR (ID);</li>\n      <li>Glunor (PE);</li>\n      <li>Glupa (KR);</li>\n      <li>Glustress (TH);</li>\n      <li>Glutamet (ET);</li>\n      <li>Glyciphage (IN);</li>\n      <li>Glycomet (SG);</li>\n      <li>Glycomin (KR);</li>\n      <li>Glyformin (TW);</li>\n      <li>Glymet (AE, BH, CY, EG, ET, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Guamet (HK);</li>\n      <li>Heskopaq (ID);</li>\n      <li>Humamet (PH);</li>\n      <li>Humamet XR (PH);</li>\n      <li>I-Max (PH);</li>\n      <li>Indform (VN);</li>\n      <li>Insufor (UA);</li>\n      <li>Insumed (PH);</li>\n      <li>Islotin (AR);</li>\n      <li>Lucomet (IE);</li>\n      <li>Maformin (TH);</li>\n      <li>Medfort (PE);</li>\n      <li>Mefarmil (UA);</li>\n      <li>Meglucon (DE);</li>\n      <li>Melbin (HK, JP);</li>\n      <li>Merckformin (HU);</li>\n      <li>Mescorit (DE);</li>\n      <li>Metamin (UA);</li>\n      <li>Metchek (NZ);</li>\n      <li>Metdia (VN);</li>\n      <li>Metex XR (AU);</li>\n      <li>Metfar (BD);</li>\n      <li>Metfin (ZW);</li>\n      <li>Metfogamma (DE, LV);</li>\n      <li>Metfor (AE, BH, QA);</li>\n      <li>Metfor XR (PH);</li>\n      <li>Metforal (CR, DO, EC, GT, HN, IT, LT, LV, NI, PA, SG, SV);</li>\n      <li>Metform (BD);</li>\n      <li>Metformax (LU);</li>\n      <li>Metgluco (JP);</li>\n      <li>Metgreen-SR (KR);</li>\n      <li>Metophage (IE);</li>\n      <li>Metta SR (ZW);</li>\n      <li>Miformin (TH);</li>\n      <li>Neoform (PH);</li>\n      <li>Normax (PH);</li>\n      <li>Orabet (AT, DK, GB, IE);</li>\n      <li>Predial (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Quexel (CR, DO, EC, GT, HN, NI, PA, SV);</li>\n      <li>Risidon (PT);</li>\n      <li>Siamformet (TH);</li>\n      <li>Siofor (BG, DE, PL, SI, SK);</li>\n      <li>Stagid (PT);</li>\n      <li>Sukkarto SR (GB);</li>\n      <li>Thiabet (DE);</li>\n      <li>Walaphage (IN);</li>\n      <li>Xmet (ET);</li>\n      <li>Yaltormin (IE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    ACOG Committee on Practice Bulletins-Gynecology, &quot;ACOG Practice Bulletin No. 108: Polycystic Ovary Syndrome,&quot; <i>Obstet Gynecol</i>, 2009, 114(4):936-49.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Association of Clinical Endocrinologists Polycystic Ovary Syndrome Writing Committee, &ldquo;American Association of Clinical Endocrinologists Position Statement on Metabolic and Cardiovascular Consequences of Polycystic Ovary Syndrome,&rdquo; <i>Endocr Pract </i>, 2005, 11(2):126-34.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/15915567/pubmed\" target=\"_blank\" id=\"15915567\">15915567</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins, &quot;Clinical Management Guidelines for Obstetrician-Gynecologists. Number 60, March 2005. Pregestational Diabetes Mellitus,&quot; <i>Obstet Gynecol</i>, 2005, 105(3):675-85.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/15738045/pubmed\" target=\"_blank\" id=\"15738045\">15738045</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG)Committee on Practice Bulletins&mdash;Obstetrics. ACOG Practice Bulletin No. 190: Gestational Diabetes Mellitus. <i>Obstet Gynecol</i>. 2018;131(2):e49-e64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/29370047/pubmed\" target=\"_blank\" id=\"29370047\">29370047</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Radiology Committee on Drugs and Contrast Media. ACR Manual on Contrast Media. Version 10.3. https://www.acr.org/Clinical-Resources/Contrast-Manual. Published 2017. Accessed January 3, 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Diabetes Association (ADA). 8. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2018.<i> Diabetes Care.</i> 2018a;41(suppl 1):S73-S85. doi: 10.2337/dc18-S008.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/29222379/pubmed\" target=\"_blank\" id=\"29222379\">29222379</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"29222382\"></a>American Diabetes Association (ADA). 11. Older adults: standards of medical care in diabetes-2018. <i>Diabetes Care</i>. 2018b;41(suppl 1):S119-S125. doi: 10.2337/dc18-S011.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/29222382/pubmed\" target=\"_blank\" id=\"29222382\">29222382</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"29222384\"></a>American Diabetes Association (ADA). 13. Management of diabetes in pregnancy: standards of medical care in diabetes-2018. <i>Diabetes Care</i>. 2018c;41(suppl 1):S137-S143. doi: 10.2337/dc18-S013.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/29222384/pubmed\" target=\"_blank\" id=\"29222384\">29222384</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Diabetes Association (ADA). 4. Lifestyle management: standards of medical care in diabetes-2018.<i> Diabetes Care.</i> 2018d;41(Suppl 1):S38-S50. doi:10.2337/dc18-S004.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/29222375/pubmed\" target=\"_blank\" id=\"29222375\">29222375</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Diabetes Association (ADA). 14. Diabetes care in the hospital: standards of medical care in diabetes-2018. <i>Diabetes Care.</i> 2018e;41(suppl 1):S144-S151. doi: 10.2337/dc18-S014.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/29222385/pubmed\" target=\"_blank\" id=\"29222385\">29222385</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Diabetes Association (ADA). 12. Children and adolescents: standards of medical care in diabetes-2018. <i>Diabetes Care.</i> 2018f;41(suppl 1):S126-S136. doi: 10.2337/dc18-S012.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/29222383/pubmed\" target=\"_blank\" id=\"29222383\">29222383</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"29222377\"></a>American Diabetes Association (ADA). 6. Glycemic targets: standards of medical care in diabetes-2018. <i>Diabetes Care</i>. 2018g;41(suppl 1):S55-S64. doi: 10.2337/dc18-S006.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/29222377/pubmed\" target=\"_blank\" id=\"29222377\">29222377</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Diabetes Association (ADA). 9. Cardiovascular disease and risk management: standards of medical care in diabetes-2018. <i>Diabetes Care</i>. 2018h;41(suppl 1): S86-S104. doi: 10.2337/dc18-S009.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/29222380/pubmed\" target=\"_blank\" id=\"29222380\">29222380</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/27060684/pubmed\" target=\"_blank\" id=\"27060684\">27060684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bailey CJ and Turner RC, &ldquo;Metformin,&rdquo; <i>N Engl J Med</i>, 1996, 334(9):574-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/8569826/pubmed\" target=\"_blank\" id=\"8569826\">8569826</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Balani J, Hyer SL, Rodin DA, et al, &quot;Pregnancy Outcomes in Women With Gestational Diabetes Treated With Metformin or Insulin: A Case-Control Study,&quot; <i>Diabet Med</i>, 2009, 26(8):798-802.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/19709150/pubmed\" target=\"_blank\" id=\"19709150\">19709150</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Blumer I, Hadar E, Hadden DR, et al. Diabetes and pregnancy: an endocrine society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2013;98(11):4227-4249.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/24194617 /pubmed\" target=\"_blank\" id=\"24194617 \">24194617 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brackett CC. Clarifying metformin's role and risks in liver dysfunction. <i>J Am Pharm Assoc (2003)</i>. 2010;50(3):407-410. doi: 10.1331/JAPhA.2010.08090<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/20452916/pubmed\" target=\"_blank\" id=\"20452916\">20452916</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Briggs GG, Ambrose PJ, Nageotte MP, et al, &quot;Excretion of Metformin Into Breast Milk and the Effect on Nursing Infants,&quot; <i>Obstet Gynecol</i>, 2005, 105(6):1437-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/15932841/pubmed\" target=\"_blank\" id=\"15932841\">15932841</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19515536\"></a>Carrizo E, Fern&aacute;ndez V, Connell L, et al. Extended release metformin for metabolic control assistance during prolonged clozapine administration: A 14 week, double-blind, parallel group, placebo-controlled study. <i>Schizophrenia Res. </i>2009;113(1):19-26.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/19515536/pubmed\" target=\"_blank\" id=\"19515536\">19515536</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Charles B, Norris R, Xiao X, et al, &quot;Population Pharmacokinetics of Metformin in Late Pregnancy,&quot; <i>Ther Drug Monit</i>, 2006, 28(1):67-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/16418696/pubmed\" target=\"_blank\" id=\"16418696\">16418696</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23759461\"></a>Chen CH, Huang MC, Kao CF, et al. Effects of adjunctive metformin on metabolic traits in nondiabetic clozapine-treated patients with schizophrenia and the effect of metformin discontinuation on body weight: a 24-week, randomized, double-blind, placebo-controlled study. <i>J Clin Psychiatry</i>. 2013;74(5):e424-e430. doi: 10.4088/JCP.12m08186.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/23759461/pubmed\" target=\"_blank\" id=\"23759461\">23759461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Coetzee EJ and Jackson WP, &quot;Metformin in Management of Pregnant Insulin-Independent Diabetics,&quot; <i>Diabetologia</i>, 1979, 16(4):241-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/428695/pubmed\" target=\"_blank\" id=\"428695\">428695</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Coetzee EJ and Jackson WP, &quot;Oral Hypoglycaemics in the First Trimester and Fetal Outcome,&quot; <i>S Afr Med J</i>, 1984, 65(16):635-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/6369573/pubmed\" target=\"_blank\" id=\"6369573\">6369573</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27147592\"></a>Cooper SJ, Reynolds GP, Barnes TRE, et al. BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment. <i>J Psychopharmacol. </i>2016;30(8):717-748. doi: 10.1177/0269881116645254.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/27147592/pubmed\" target=\"_blank\" id=\"27147592\">27147592</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Copeland KC, Silverstein J, Moore KR, et al. Management of newly diagnosed type 2 diabetes mellitus (T2DM) in children and adolescents. <i>Pediatrics</i>. 2013;131(2):364-382.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/23359574/pubmed\" target=\"_blank\" id=\"23359574\">23359574</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Corbett S, Shmorgun D, Claman P, Reproductive Endocrinology Infertility Committee, Healey S, Gysler M. The prevention of ovarian hyperstimulation syndrome. <i>J Obstet Gynaecol Can</i>. 2014;36(11):1024-1036.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/25574681/pubmed\" target=\"_blank\" id=\"25574681\">25574681</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Costello M, Shrestha B, Eden J, Sjoblom P, Johnson N. Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. <i>Cochrane Database Syst Rev</i>. 2007;(1):CD005552. Review.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/17253562/pubmed\" target=\"_blank\" id=\"17253562\">17253562</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Crowley MJ, Diamantidis CJ, McDuffie JR, et al. Clinical outcomes of metformin use in populations with chronic kidney disease, congestive heart failure, or chronic liver disease: a systematic review. <i>Ann Intern Med</i>. 2017;166(3):191-200. doi: 10.7326/M16-1901.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/28055049/pubmed\" target=\"_blank\" id=\"28055049\">28055049</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DeFronzo RA, &ldquo;Pharmacologic Therapy for Type 2 Diabetes Mellitus,&rdquo; <i>Ann Intern Med</i>, 1999, 131(4):281-303.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/10454950/pubmed\" target=\"_blank\" id=\"10454950\">10454950</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    de Oliveira Baraldi C, Lanchote VL, de Jesus Antunes N, et al, &quot;Metformin Pharmacokinetics in Nondiabetic Pregnant Women With Polycystic Ovary Syndrome,&quot; <i>Eur J Clin Pharmacol</i>, 2011, 67(10):1027-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/21538144/pubmed\" target=\"_blank\" id=\"21538144\">21538144</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27716110\"></a>de Silva VA, Suraweera C, Ratnatunga SS, Dayabandara M, Wanniarachchi N, Hanwella R. Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis. <i>BMC Psychiatry</i>. 2016;16(1):341.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/27716110/pubmed\" target=\"_blank\" id=\"27716110\">27716110</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dunn CJ and Peters DH, &ldquo;Metformin: A Review of Its Pharmacologic Properties and Therapeutic Use in Diabetes Mellitus,&rdquo; <i>Drugs</i>, 1995, 49(5):721-49.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/7601013/pubmed\" target=\"_blank\" id=\"7601013\">7601013</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ekpebegh CO, Coetzee EJ, van der Merwe L, et al, &quot;A 10-Year Retrospective Analysis of Pregnancy Outcome in Pregestational Type 2 Diabetes: Comparison of Insulin and Oral Glucose-Lowering Agents,&quot; <i>Diabet Med</i>, 2007, 24(3):253-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/17305787/pubmed\" target=\"_blank\" id=\"17305787\">17305787</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eurich DT, Weir DL, Majumdar SR, et al. Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients. <i>Circ Heart Fail</i>. 2013;6(3):395-402. doi: 10.1161/CIRCHEARTFAILURE.112.000162.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/23508758/pubmed\" target=\"_blank\" id=\"23508758\">23508758</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eyal S, Easterling TR, Carr D, et al, &quot;Pharmacokinetics of Metformin During Pregnancy,&quot; <i>Drug Metab Dispos</i>, 2010, 38(5):833-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/20118196/pubmed\" target=\"_blank\" id=\"20118196\">20118196</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fauser BC, Tarlatzis BC, Rebar RW, et al, &quot;Consensus on Women's Health Aspects of Polycystic Ovary Syndrome (PCOS): The Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group,&quot; <i>Fertil Steril</i>, 2012, 97(1):28-38.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/22153789 /pubmed\" target=\"_blank\" id=\"22153789 \">22153789 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fortamet (metformin) [prescribing information]. Ft. Lauderdale, FL: First Horizon; July 2008.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2017 executive summary. <i>Endocr Pract</i>. 2017;23(2):207-238. doi: 10.4158/EP161682.CS.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/28095040/pubmed\" target=\"_blank\" id=\"28095040\">28095040</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gardiner SJ, Kirkpatrick CM, Begg EJ, et al, &quot;Transfer of Metformin Into Human Milk,&quot; <i>Clin Pharmacol Ther</i>, 2003, 73(1):71-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/12545145/pubmed\" target=\"_blank\" id=\"12545145\">12545145</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Glucophage (metformin) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb; February 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Glucophage (metformin) [product monograph]. Laval, Quebec, Canada: Sanofi-aventis Canada Inc; August 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Glucophage XR (metformin) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb; February 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Glueck CJ, Goldenberg N, Pranikoff J, et al, &quot;Effects of Metformin-Diet Intervention Before and Throughout Pregnancy on Obstetric and Neonatal Outcomes in Patients With Polycystic Ovary Syndrome,&quot; <i>Curr Med Res Opin</i>, 2013, 29(1):55-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/23205605/pubmed\" target=\"_blank\" id=\"23205605\">23205605</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Glumetza (metformin) [prescribing information]. Menlo Park, CA: Depomed; September 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hale TW, Kristensen JH, Hackett LP, et al, &quot;Transfer of Metformin Into Human Milk,&quot; <i>Diabetologia</i>, 2002, 45(11):1509-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/12436333/pubmed\" target=\"_blank\" id=\"12436333\">12436333</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hughes RC and Rowan JA, &ldquo;Pregnancy in Women With Type 2 Diabetes: Who Takes Metformin and What Is the Outcome?&rdquo; <i>Diabet Med</i>, 2006, 23(3):318-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/16492217/pubmed\" target=\"_blank\" id=\"16492217\">16492217</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hughes RC, Gardiner SJ, Begg EJ, et al, &quot;Effect of Pregnancy on the Pharmacokinetics of Metformin,&quot; <i>Diabet Med</i>, 2006, 23(3):323-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/16492218 /pubmed\" target=\"_blank\" id=\"16492218 \">16492218 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Inzucchi SE, Lipska KJ, Mayo H, et al. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. <i>JAMA</i>. 2014;312(24):2668-2675. doi: 10.1001/jama.2014.15298.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/25536258/pubmed\" target=\"_blank\" id=\"25536258\">25536258</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Johnson NP, Stewart AW, Falkiner J, et al. REACT-NZ (REproduction And Collaborative Trials in New Zealand), a multi-centre fertility trials group. PCOSMIC: a multi-centre randomized trial in women with PolyCystic Ovary Syndrome evaluating Metformin for Infertility with Clomiphene. <i>Hum Reprod</i>. 2010;25(7):1675-1683.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/20435692/pubmed\" target=\"_blank\" id=\"20435692\">20435692</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Josephkutty S and Potter JM, &ldquo;Comparison of Tolbutamide and Metformin in Elderly Diabetic Patients,&rdquo; <i>Diabet Med</i>, 1990, 7(16):510-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/2142054/pubmed\" target=\"_blank\" id=\"2142054\">2142054</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kancherla V, Elliott JL Jr, Patel BB, et al. Long-term Metformin Therapy and Monitoring for Vitamin B12 Deficiency Among Older Veterans. <i>J Am Geriatr Soc.</i> 2017;65(5):1061-1066.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/28182265/pubmed\" target=\"_blank\" id=\"28182265\">28182265</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kirkman M, Briscoe VJ, Clark N, et al, &quot;Diabetes in Older Adults: A Consensus Report,&quot; <i>J Am Geriatr Soc</i>, 2012; doi: 10.1111/jgs.12035.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/23106132/pubmed\" target=\"_blank\" id=\"23106132\">23106132</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11832527\"></a>Knowler WC, Barrett-Connor E, Fowler SE, et al, &quot;Reduction in the Incidence of Type 2 Diabetes With Lifestyle Intervention or Metformin,&quot; <i>N Engl J Med</i>, 2002, 346(6):393-403.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/11832527/pubmed\" target=\"_blank\" id=\"11832527\">11832527</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lalau JD, Vermersch A, Hary L, et al, &ldquo;Type 2 Diabetes in the Elderly: An Assessment of Metformin,&rdquo; <i>Int J Clin Pharmacol Ther Toxicol</i>, 1990, 28(8):329-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/2272714/pubmed\" target=\"_blank\" id=\"2272714\">2272714</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24151290\"></a>Legro RS, Arslanian SA, Ehrmann DA, et al. Endocrine Society. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2013;98(12):4565-4592.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/24151290/pubmed\" target=\"_blank\" id=\"24151290\">24151290</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Legro RS, Barnhart HX, Schlaff WD, et al; Cooperative Multicenter Reproductive Medicine Network. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. <i>N Engl J Med</i>. 2007;356(6):551-566.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/17287476/pubmed\" target=\"_blank\" id=\"17287476\">17287476</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care. 2011;34(6):1431-1437.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/21617112/pubmed\" target=\"_blank\" id=\"21617112\">21617112</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McCulloch DK. Metformin in the treatment of adults with type 2 diabetes mellitus. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed December 11, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22303523\"></a>McIntyre RS, Alsuwaidan M, Goldstein BI, et al. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid metabolic disorders. <i>Ann Clin Psych. </i>2012;24(1):69-81.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/22303523/pubmed\" target=\"_blank\" id=\"22303523\">22303523</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Metzger BE, Buchanan TA, Coustan DR, et al, &quot;Summary and Recommendations of the Fifth International Workshop-Conference on Gestational Diabetes Mellitus,&quot; <i>Diabetes Care</i>, 2007, 30(Suppl 2):S251-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/17596481/pubmed\" target=\"_blank\" id=\"17596481\">17596481</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Meyer C, McGrath BP, Teede HJ. Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome. <i>Diabetes Care</i>. 2007;30(3):471-478.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/17327307/pubmed\" target=\"_blank\" id=\"17327307\">17327307</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24636967\"></a>Mizuno Y, Suzuki T, Nakagawa A, et al. Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: A systematic review and meta-analysis. <i>Schizophr Bull.</i> 2014;40(6):1385-1403. doi: 10.1093/schbul/sbu030.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/24636967/pubmed\" target=\"_blank\" id=\"24636967\">24636967</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Moghetti P, Castello R, Negri C, et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. <i>J Clin Endocrinol Metab</i>. 2000;85(1):139-146.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/10634377/pubmed\" target=\"_blank\" id=\"10634377\">10634377</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Moll E, Bossuyt PM, Korevaar JC, Lambalk CB, van der Veen F. Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. <i>BMJ</i>. 2006;332(7556):1485.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/16769748/pubmed\" target=\"_blank\" id=\"16769748\">16769748</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Morin-Papunen L, Rantala AS, Unkila-Kallio L, et al. Metformin improves pregnancy and live-birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double-blind, placebo-controlled randomized trial. <i>J Clin Endocrinol Metab</i>. 2012;97(5):1492-1500.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/22419702/pubmed\" target=\"_blank\" id=\"22419702\">22419702</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Morin-Papunen L, Vauhkonen I, Koivunen R, Ruokonen A, Martikainen H, Tapanainen JS. Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study. <i>J Clin Endocrinol Metab</i>. 2003;88(1):148-156.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/12519844/pubmed\" target=\"_blank\" id=\"12519844\">12519844</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nathan DM, Buse JB, Davidson MB, et al; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009 Jan;32(1):193-203. doi: 10.2337/dc08-9025. Epub 2008 Oct 22. PubMed Central PMCID: PMC2606813.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/18945920/pubmed\" target=\"_blank\" id=\"18945920\">18945920</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nestler JE, &ldquo;Metformin for the Treatment of the Polycystic Ovary Syndrome,&rdquo; <i>N Engl J Med</i>, 2008, 358(1):47-54.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/18172174/pubmed\" target=\"_blank\" id=\"18172174\">18172174</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Niromanesh S, Alavi A, Sharbaf FR, et al, &quot;Metformin Compared With Insulin in the Management of Gestational Diabetes Mellitus: A Randomized Clinical Trial,&quot; <i>Diabetes Res Clin Pract</i>, 2012, 98(3):422-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/23068960/pubmed\" target=\"_blank\" id=\"23068960\">23068960</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association [published correction appears in <i>Circulation</i>. 2016;134(12):e261]. <i>Circulation</i>. 2016;134(6):e32-e69.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/27400984/pubmed\" target=\"_blank\" id=\"27400984\">27400984</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Palomba S, Falbo A, Carrillo L, et al; METformin in High Responder Italian Group. Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin-stimulated in vitro fertilization cycles: a randomized, controlled trial. <i>Fertil Steril</i>. 2011;96(6):1384-1390.e4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/21982727/pubmed\" target=\"_blank\" id=\"21982727\">21982727</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Palomba S, Falbo A, La Sala GB. Effects of metformin in women with polycystic ovary syndrome treated with gonadotrophins for in vitro fertilisation and intracytoplasmic sperm injection cycles: a systematic review and meta-analysis of randomised controlled trials. <i>BJOG</i>. 2013;120(3):267-276.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/23194199/pubmed\" target=\"_blank\" id=\"23194199\">23194199</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Practice Committee of American Society for Reproductive Medicine (ASRM), &quot;Use of Insulin-Sensitizing Agents in the Treatment of Polycystic Ovary Syndrome,&quot; <i>Fertil Steril</i>, 2008, 90(5 Suppl):S69-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/19007650/pubmed\" target=\"_blank\" id=\"19007650\">19007650</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26872112\"></a>Rado J, von Ammon Cavanaugh S. A naturalistic randomized placebo-controlled trial of extended-release metformin to prevent weight gain associated with olanzapine in a US community-dwelling population. <i>J Clin Psychopharmacol. </i>2016;36(2):163-168. doi: 10.1097/JCP.0000000000000469.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/26872112/pubmed\" target=\"_blank\" id=\"26872112\">26872112</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reader D, Franz MJ. Lactation, diabetes, and nutrition recommendations. <i>Curr Diab Rep</i>. 2004;4(5):370-376.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/15461903 /pubmed\" target=\"_blank\" id=\"15461903 \">15461903 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Riomet [prescribing information]. Jacksonville, FL: Ranbaxy; July 2005.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rowan JA, Gao W, Hague WM, et al, &quot;Glycemia and Its Relationship to Outcomes in the Metformin in Gestational Diabetes Trial,&quot; <i>Diabetes Care</i>, 2010, 33(1):9-16.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/19846793/pubmed\" target=\"_blank\" id=\"19846793\">19846793</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rowan JA, Hague WM, Gao W, et al, &ldquo;Metformin Versus Insulin for the Treatment of Gestational Diabetes,&rdquo; <i>N Engl J Med</i>, 2008, 358(19):2003-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/18463376/pubmed\" target=\"_blank\" id=\"18463376\">18463376</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tang T, Glanville J, Orsi N, Barth JH, Balen AH. The use of metformin for women with PCOS undergoing IVF treatment. <i>Hum Reprod</i>. 2006;21(6):1416-1425.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/16501038/pubmed\" target=\"_blank\" id=\"16501038\">16501038</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Teede HJ, Misso ML, Deeks AA, et al. Assessment and management of polycystic ovary syndrome: summary of an evidence-based guideline. <i>Med J Aust</i>. 2011;195(6):S65-112.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/21929505/pubmed\" target=\"_blank\" id=\"21929505\">21929505</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tertti K, Ekblad U, Vahlberg T, et al, &quot;Comparison of Metformin and Insulin in the Treatment of Gestational Diabetes: A Retrospective, Case-Control Study,&quot; <i>Rev Diabet Stud</i>, 2008, 5(2):95-101.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/18795211/pubmed\" target=\"_blank\" id=\"18795211\">18795211</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tso LO, Costello MF, Albuquerque LE, Andriolo RB, Macedo CR. Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. <i>Cochrane Database Syst Rev</i>. 2014 Nov 18;11:CD006105.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/25406011/pubmed\" target=\"_blank\" id=\"25406011\">25406011</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vanky E, Zahlsen K, Spigset O, et al, &quot;Placental Passage of Metformin in Women With Polycystic Ovary Syndrome,&quot; <i>Fertil Steril</i>, 2005, 83(5):1575-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/15866611/pubmed\" target=\"_blank\" id=\"15866611\">15866611</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vause TD, Cheung AP, Sierra S, et al. Ovulation induction in polycystic ovary syndrome: No. 242, May 2010. <i>Int J Gynaecol Obstet</i>. 2010;111(1):95-100. <i>Erratum in:</i><i>J Obstet Gynaecol Can</i>. 2011;33(1):12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/20500959/pubmed\" target=\"_blank\" id=\"20500959\">20500959</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22398127\"></a>Wang M, Tong JH, Zhu G, Liang GM, Yan HF, Wang XZ. Metformin for treatment of antipsychotic-induced weight gain: A randomized, placebo-controlled study. <i>Schizophrenia Res. </i>2012;138(1):54-57. doi: 10.1016/j.schres.2012.02.021.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/22398127/pubmed\" target=\"_blank\" id=\"22398127\">22398127</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zeitler P, Fu J, Tandon N, et al. Type 2 diabetes in the child and adolescent. <i>Pediatr Diabetes</i>. 2014;15(Suppl 20):26-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/25182306/pubmed\" target=\"_blank\" id=\"25182306\">25182306</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zhang X, Harmsen WS, Mettler TA, et al. Continuation of metformin use after a diagnosis of cirrhosis significantly improves survival of patients with diabetes. <i>Hepatology</i>. 2014;60(6):2008-2016. doi: 10.1002/hep.27199<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/24798175/pubmed\" target=\"_blank\" id=\"24798175\">24798175</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26280837\"></a>Zheng W, Li XB, Tang YL, Xiang YQ, Wang CY, de Leon J. Metformin for weight gain and metabolic abnormalities associated with antipsychotic treatment: Meta-analysis of randomized, placebo-controlled trials. <i>J Clin Psychopharmacol. </i>2015;35(5):499-509. doi: 10.1097/JCP.0000000000000392.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metformin-drug-information/abstract-text/26280837/pubmed\" target=\"_blank\" id=\"26280837\">26280837</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9621 Version 294.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709034\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F193858\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F193859\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F193907\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F193863\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F193885\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F193864\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F193865\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F193866\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F193832\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F193817\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F25484130\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F20344698\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F193837\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F193836\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25730693\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F193915\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F193824\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F193840\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F193821\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299680\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F193826\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F193854\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F193828\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F193843\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F193844\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F193845\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F193830\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F193833\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F193820\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F193839\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F193842\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F193846\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9621|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=metformin-patient-drug-information\" class=\"drug drug_patient\">Metformin: Patient drug information</a></li><li><a href=\"topic.htm?path=metformin-pediatric-drug-information\" class=\"drug drug_pediatric\">Metformin: Pediatric drug information</a></li></ul></div></div>","javascript":null}